The study team previously shown that a cholesterol metabolite, dendrogenin A (DDA) differentiates anaplastic thyroid cancer cell lines and that its mRNA expression is diminished in human radioiodine refractory thyroid cancer samples. The team aim to quantify via mass spectrometry and immunohistochemistry DDA and other cholesterol metabolites in thyroid cancer versus healthy thyroid tissue human samples.
Retrospective study to analyze tissue samples of patients after thyroid surgery at Claudius Regaud Institute Toulouse, France, for thyroid cancer or thyroid aggressive lymphoma or benign thyroid pathology or other head\&neck pathology necessitating total thyroidectomy despite normal thyroid. Analysis focused on cholesterol metabolites quatification by mass spectrometry in liquid and gas phase.
Study Type
OBSERVATIONAL
Enrollment
30
On samples investigators will quantify cholesterol metabolite and dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (ou OCDO) metabolites in malignant tissue sample on one hand, and in sane samples on other hand. The investigators will compare the rate of deregulation between sane and malignant ones.
Institut Claudius regaud IUCT Oncopole
Toulouse, France
Rate of dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (OCDO) in thyroid tissue (healthy or malignant)
The measurement expressed in ng / g of thyroid tissue
Time frame: 12 months after the beginning of the study
Presence of enzymes involved in dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (OCDO) production
intensity of signal in Liquid Chromatography-Mass Spectrometry
Time frame: 12 months after the beginning of the study
Number of enzymes involved in denrognenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (OCDO) production
Quantify by immunohistochemistry
Time frame: 12 months after the beginning of the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.